The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients

被引:262
作者
Filipsson, Helena
Monson, John P.
Koltowska-Haggstrom, Maria
Mattsson, Anders
Johannsson, Gudmundur
机构
[1] Gothenburg Univ, Sahlgrenska Acad, Dept Endocrinol, SE-41345 Gothenburg, Sweden
[2] Queen Mary Univ London, St Bartholomews Hosp, London EC1A 7BE, England
[3] Pfizer, Endocrine Care, KIGS,KIMS,ACROSTUDY Med Outcomes, SE-19190 Sollentuna, Sweden
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
关键词
D O I
10.1210/jc.2006-0524
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid ( GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS ( Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/ dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
引用
收藏
页码:3954 / 3961
页数:8
相关论文
共 42 条
  • [11] Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism
    Christiansen, JJ
    Gravholt, CH
    Fisker, S
    Moller, N
    Andersen, M
    Svenstrup, B
    Bennett, P
    Ivarsen, P
    Christiansen, JS
    Jorgensen, JOL
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) : 77 - 85
  • [12] Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women
    Dhatariya, K
    Bigelow, ML
    Nair, KS
    [J]. DIABETES, 2005, 54 (03) : 765 - 769
  • [13] Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
    Drake, WM
    Coyte, D
    Camacho-Hübner, C
    Jivanji, NM
    Kaltsas, G
    Wood, DF
    Trainer, PJ
    Grossman, AB
    Besser, GM
    Monson, JP
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) : 3913 - 3919
  • [14] DUNNE FP, 1995, CLIN ENDOCRINOL, V43, P623, DOI 10.1111/j.1365-2265.1995.tb02928.x
  • [15] DAILY CORTISOL PRODUCTION-RATE IN MAN DETERMINED BY STABLE ISOTOPE-DILUTION MASS-SPECTROMETRY
    ESTEBAN, NV
    LOUGHLIN, T
    YERGEY, AL
    ZAWADZKI, JK
    BOOTH, JD
    WINTERER, JC
    LORIAUX, DL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (01) : 39 - 45
  • [16] Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH
    Finamor, FE
    Lengyel, AMJ
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (11) : 871 - 875
  • [17] FOSSATI P, 1982, CLIN CHEM, V28, P2077
  • [18] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [19] The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults:: evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity
    Gelding, SV
    Taylor, NF
    Wood, PJ
    Noonan, K
    Weaver, JU
    Wood, DF
    Monson, JP
    [J]. CLINICAL ENDOCRINOLOGY, 1998, 48 (02) : 153 - 162
  • [20] An assessment of optimal hydrocortisone replacement therapy
    Howlett, TA
    [J]. CLINICAL ENDOCRINOLOGY, 1997, 46 (03) : 263 - 268